Last updated: February 14, 2026
What is the drug associated with NDC 70069-0131?
NDC 70069-0131 corresponds to Tafasitamab-cxix (Monjuvi), a monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) in 2020. It targets CD19-positive B-cell non-Hodgkin lymphoma, primarily for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with lenalidomide.
What is the current market size for Tafasitamab-cxix?
The market for B-cell non-Hodgkin lymphoma therapies is substantial, with global sales exceeding $8 billion in 2022[1]. Specifically, Monjuvi's initial FDA approval targeted a niche segment:
- U.S. Market Size (2022): Estimated at $350 million.
- Key Competitors: Rituximab, pola, liso, and polatuzumab.
- Market Share: Monjuvi holds approximately 10-15% of the relapsed/refractory DLBCL market.
Unique features driving market adoption include its targeted action and combination approval with lenalidomide.
How has Monjuvi been adopted within its target indications?
- Treatment Adoption Rate: Roughly 20-25% of eligible patients in serving centers.
- Reimbursement & Coverage: Most major insurers provide coverage, with prior-authorization requirements.
- Pricing Strategy: Monjuvi's list price is approximately $16,300 per infusion. Based on typical cycles, the average treatment course costs around $200,000 to $300,000.
What are the key factors influencing future pricing dynamics?
-
Competition Pressure: Competitors like CAR-T therapies (e.g., Axicabtagene ciloleucel, Yescarta, and Lisocabtagene maraleucel) are moving into similar indications, potentially decreasing Monjuvi’s market share. These therapies offer curative potential but come with higher costs and logistical complexity.
-
Price Sensitivity: While the list price is high, payor negotiations and utilization constraints keep average real-world costs lower, estimated at $150,000–$250,000 per course.
-
Regulatory Announcements: Pending approvals for broader indications or combination regimens could expand label use and influence price.
-
Market Penetration Strategies: Expanded access and inclusion in earlier lines of therapy can increase utilization, potentially driving up aggregate revenues.
What are the projections for future price trends?
| Year |
Price per Course |
Notes |
| 2023 |
$200,000–$250,000 |
Stable with slight discounts for bulk or formularies |
| 2025 |
$180,000–$240,000 |
Competitive pressure from CAR-Ts and biosimilars |
| 2028 |
$150,000–$220,000 |
Potential biosimilar entry or revised reimbursement policies |
Note: Price decreases are expected due to increased competition and potential biosimilar development. However, personalized medicine trends could sustain or increase price if Monjuvi maintains a distinct niche.
What are the key considerations for investors and R&D?
- Patent and exclusivity status: Monjuvi's patent protection extends into the late 2020s, delaying biosimilar entry.
- Regulatory developments: Additional approvals or label expansions could support higher prices or sales volume.
- Market trends: Shifts toward cell therapies may limit monoclonal antibody growth unless Monjuvi adapts or gains new indications.
Conclusion
NDC 70069-0131, Tafasitamab-cxix (Monjuvi), has established a niche in relapsed/refractory DLBCL with an initial price around $200,000 per course. Future pricing will likely decline gradually due to market competition, especially from CAR-T therapies, biosimilars, and potential label expansions. Market share gains depend on clinical positioning and payer acceptance. Revenue growth hinges on broader indications and increased line-of-therapy adoption.
Key Takeaways
- Monjuvi's initial list price is approximately $200,000–$250,000 per treatment course.
- The current U.S. market size is estimated at $350 million, with potential for growth.
- Competition from CAR-Ts and biosimilars will exert downward pressure on prices.
- Price projections suggest gradual decline over the next 5 years, adjusted for market dynamics.
- Regulatory and label expansion opportunities could offset some downward price trends.
FAQs
Q1: How does Monjuvi’s pricing compare to other monoclonal antibodies in hematology?
A1: Its list price (~$200,000 per course) is comparable to similar therapies for relapsed DLBCL but generally lower than CAR-T therapies, which can cost between $373,000 and $475,000 per treatment.
Q2: What factors could lead to a price increase for Monjuvi?
A2: Successful approval of additional indications, improved reimbursement terms, or significant clinical data demonstrating superior efficacy could support higher prices.
Q3: How will biosimilars impact Monjuvi’s market?
A3: Introduction of biosimilars could reduce the price by 20-40%, pressuring Monjuvi’s revenue margins but potentially increasing overall market penetration.
Q4: What is the likelihood of Monjuvi being replaced in practice by CAR-T therapies?
A4: CAR-Ts offer curative potential but are more complex and expensive, limiting replacement. Monjuvi remains relevant especially in patients ineligible for CAR-T therapy.
Q5: Are there ongoing clinical trials that could increase Monjuvi’s market value?
A5: Yes, ongoing trials exploring combination therapies and expanded indications could extend Monjuvi’s use, supporting higher prices and sales volumes.
Sources
[1] IQVIA, "Global Hematology and Oncology Market Data," 2022.
[2] FDA, "FDA Approvals," 2020.
[3] EvaluatePharma, "Market Intelligence," 2022.
[4] Bloomberg Intelligence, "Oncology Market Pricing," 2023.
[5] Medicare Coverage Data, 2023.
